<DOC>
	<DOCNO>NCT00064194</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain substance try prevent development recurrence cancer . Vitamin E , selenium , soy protein may effective preventing development prostate cancer . PURPOSE : Randomized phase III trial study effectiveness combine vitamin E , selenium , soy protein prevent prostate cancer patient high-grade prostate neoplasia .</brief_summary>
	<brief_title>Vitamin E , Selenium , Soy Protein Preventing Cancer Patients With High-Grade Prostate Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether nutritional supplementation soy protein isolate , vitamin E , selenium delay time development invasive prostate cancer ( disease-free survival ) patient high-grade prostatic intraepithelial neoplasia . - Determine effect supplementation intermediate endpoint may reflect lessen risk invasive prostate cancer ( e.g. , serum PSA level , hormone level , lycopene , malondialdehyde , vitamin E , reduce thiol group ) patient . - Determine safety supplementation patient . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral vitamin E , oral selenium , oral soy protein isolate twice daily . - Arm II : Patients receive oral placebo twice daily . In arm , treatment continue 3 year absence invasive prostate cancer ( demonstrate biopsy ) unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 306 patient ( 153 per treatment arm ) accrue study within 6 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Prostatic Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm highgrade prostatic intraepithelial neoplasia ( HGPIN ) No evidence invasive prostate cancer least 2 biopsy within past 18 month At least 1 biopsy must show evidence HGPIN within past 6 month No prior invasive prostate cancer PATIENT CHARACTERISTICS : Age Not specify Performance status Not specify Life expectancy More 5 year Hematopoietic Platelet count least 75,000/mm^3 No coagulopathies Hepatic Bilirubin great 2 time upper limit normal ( ULN ) PT ( INR ) great 1.5 time ULN PTT great 1.5 time ULN No hepatic insufficiency Renal Creatinine great 2 time ULN No renal insufficiency Other No prior nonmelanoma skin cancer ( e.g. , squamous cell basal cell carcinoma ) No malignancy within past 5 year except superficial bladder cancer No know bowel malabsorption No dietary behavior ( e.g. , morbid obesity eat disorder ) would limit adherence study therapy No major illness , include psychiatric illness , would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 3 month since prior androgen therapy More 3 month since prior hormonal therapy benign prostatic hyperplasia ( e.g. , finasteride ) No concurrent finasteride No concurrent androgen therapy Radiotherapy More 2 year since prior radiotherapy pelvic region Surgery Not specify Other More 2 week since prior supplemental vitamin E selenium No concurrent vitamin E ( great 100 IU/day ) , selenium , soy protein isolate ( 2 servings/week ) No concurrent treatment highgrade prostatic intraepithelial neoplasia</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>high grade prostatic intraepithelial neoplasia</keyword>
</DOC>